Background: Traumatic coagulopathy contributes to early death by exsanguination and late
death in multiple organ failure. Recombinant Factor VIIa (rFVIIa, NovoSeven) is a …

Background: This study was designed to compare mortality and blood product use in
patients who received recombinant activated factor VII (rFVIIa) for traumatic hemorrhage to a …

Background: Recombinant activated coagulation factor VII (rFVIIa) is increasingly being
administered to massively bleeding trauma patients. rFVIIa has been shown to correct …

Background: Uncontrolled bleeding is a leading cause of death in trauma. Two randomized,
placebo-controlled, double-blind trials (one in blunt trauma and one in penetrating trauma) …

STUDY OBJECTIVE: To examine our institutional experience with recombinant Factor VIIa
(rFVIIa) as a treatment for exsanguinating hemorrhage in critically ill trauma patients …

Massive transfusion requirements in multitrauma pa-tients can further complicate
management by promoting a hypothermic and dilutional coagulopathy. We present a case of …

Background Recombinant activated factor VII (rFVIIa) was approved for treatment of
hemorrhages in patients with hemophilia who develop inhibitors to factors VIII or IX …

Background: The majority of patients with potentially survivable combat-related injuries die
from hemorrhage. Our objective was to determine whether the use of recombinant activated …

Background: Recombinant activated factor VII (rFVIIa) has been approved by the US Food
and Drug Administration (FDA) for almost a decade for hemophilic patients with inhibitors. Its …

Trauma is rapidly replacing stroke and cardiovascular disease as a leading cause of death
in Western countries such as the United States, and almost a third (30%) of trauma deaths …